Table 1.
Clinical and demographic characteristics of gout cases and control subjects
| GA group(n = 583) | HC group (n = 459) | P value | |
|---|---|---|---|
| Age (years)a | 48.18 ± 12.16 | 47.35 ± 11.28 | > 0.05 |
| Gender (male/female)b | 558/25 | 436/23 | > 0.05 |
| Disease duration (years) | 6.50 ± 7.30 | – | – |
| Tophi, n (%) | 71(12.2) | – | – |
| BMI(kg/m2)a | 25.99 ± 3.32 | 23.18 ± 4.47 | < 0.01 |
| sUA (μmol/L)a | 509 ± 132.6 | 308 ± 56.3 | < 0.01 |
| GLU (mmol/L)a | 6.27 ± 1.82 | 5.18 ± 0.49 | < 0.01 |
| WBC (×109/L)a | 6.89 ± 2.41 | 4.78 ± 1.55 | < 0.01 |
| GR (×109/L)a | 4.75 ± 2.25 | 3.48 ± 0.88 | < 0.01 |
| LY (×109/L)a | 1.79 ± 0.73 | 2.13 ± 0.65 | > 0.05 |
| Mo (×109/L)a | 0.69 ± 0.27 | 0.49 ± 0.19 | < 0.01 |
| TG (mmol/L)a | 2.34 ± 1.60 | 1.15 ± 0.67 | < 0.01 |
| GLOB (g/L) a | 29.96 ± 5.22 | 26.63 ± 4.31 | < 0.01 |
| TC (mmol/L)a | 4.88 ± 0.98 | 4.45 ± 0.44 | > 0.05 |
| HDL (mmol/L)a | 1.16 ± 0.41 | 1.36 ± 0.31 | < 0.05 |
| LDL (mmol/L)a | 2.62 ± 0.87 | 2.65 ± 0.55 | > 0.05 |
| VLDL (mmol/L)a | 1.13 ± 0.69 | 0.53 ± 0.22 | < 0.01 |
| apoA1 (mmol/L)a | 1.30 ± 0.35 | 1.24 ± 0.20 | > 0.05 |
| apoB100 (mmol/L)a | 0.93 ± 0.26 | 0.78 ± 0.14 | < 0.05 |
| ESR | 30.26 ± 25.39 | ||
| CRP | 18.36 ± 26.21 |
GA gouty arthritis, HC healthy control subjects, BMI body mass index, sUA serum uric acid, GLU serum glucose, WBC white blood cell counts, GR neutrophile granulocytecounts, LY lymphocyte counts, Mo monocyte counts, TG triglycerides, TC total cholesterol, HDL high density lipoprotein, LDL low density lipoprotein, VLDL very low density lipoprotein, apoA1 apolipoprotein A1, apoB100 apolipoprotein B100, ESR erythrocyte sedimentation rate, CRP C-reactive protein
a t test or corrected t test
bχ2 test were performed. Statistical significance was set at P ≤ 0.05